Hansa Medical’s CFO appointed acting CEO

Press release 2 March, 2015

Hansa Medical’s CFO Göran Arvidson has been appointed acting CEO during Fredrik Lindgren’s leave of absence. Fredrik Lindgren has, due to medical reasons, been granted leave of absence by the Board of Directors.

After medical consultation, the Chief Executive Officer of Hansa Medical AB (publ), Fredrik Lindgren, has requested a leave of absence in order to focus on his health. The Board of Directors has granted his request and appointed the company’s Chief Financial Officer, Göran Arvidson, to be acting CEO

Göran Arvidson is CFO of Hansa Medical since January 27, 2015. Göran Arvidson has significant experience from the life science sector. He has been Executive Vice President and CFO of Swedish Orphan Biovitrum AB (publ),  Co-founder of Biovitrum and has held senior positions with Procordia AB and Pharmacia AB.

About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (HMED) is listed on NASDAQ First North in Stockholm with Remium Nordic AB as Certified Adviser. 

For further information, please contact:
Hansa Medical AB
Göran Arvidson, CFO and acting CEO
Mobile: +46 706 333042
E-mail: goran.arvidson@hansamedical.com

www.hansamedical.com

The information in this press release is disclosed pursuant to the Securities Markets Act or the Financial Instruments Trading Act. The information was released for public disclosure on March 2, 2015 at 08.00.